Multicenter Study of Fulvestrant (Faslodex) in Early, Recurrent Prostate Cancer Following Local Therapy: A Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2015
At a glance
- Drugs Fulvestrant (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 25 Apr 2011 Planned end date changed from 1 Jan 2013 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 25 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.